Anti-LRIT3 monoclonal antibody

Pre-made anti-LRIT3 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to LRIT3/LRIT3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1110-Ab-1/ GM-Tg-hg-IP1110-Ab-2Anti-Human LRIT3 monoclonal antibodyHuman
GM-Tg-rg-IP1110-Ab-1/ GM-Tg-rg-IP1110-Ab-2Anti-Rat LRIT3 monoclonal antibodyRat
GM-Tg-mg-IP1110-Ab-1/ GM-Tg-mg-IP1110-Ab-2Anti-Mouse LRIT3 monoclonal antibodyMouse
GM-Tg-cynog-IP1110-Ab-1/ GM-Tg-cynog-IP1110-Ab-2Anti-Cynomolgus/ Rhesus macaque LRIT3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1110-Ab-1/ GM-Tg-felg-IP1110-Ab-2Anti-Feline LRIT3 monoclonal antibodyFeline
GM-Tg-cang-IP1110-Ab-1/ GM-Tg-cang-IP1110-Ab-2Anti-Canine LRIT3 monoclonal antibodyCanine
GM-Tg-bovg-IP1110-Ab-1/ GM-Tg-bovg-IP1110-Ab-2Anti-Bovine LRIT3 monoclonal antibodyBovine
GM-Tg-equg-IP1110-Ab-1/ GM-Tg-equg-IP1110-Ab-2Anti-Equine LRIT3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1110-Ab-1/ GM-Tg-hg-IP1110-Ab-2; GM-Tg-rg-IP1110-Ab-1/ GM-Tg-rg-IP1110-Ab-2;
GM-Tg-mg-IP1110-Ab-1/ GM-Tg-mg-IP1110-Ab-2; GM-Tg-cynog-IP1110-Ab-1/ GM-Tg-cynog-IP1110-Ab-2;
GM-Tg-felg-IP1110-Ab-1/ GM-Tg-felg-IP1110-Ab-2; GM-Tg-cang-IP1110-Ab-1/ GM-Tg-cang-IP1110-Ab-2;
GM-Tg-bovg-IP1110-Ab-1/ GM-Tg-bovg-IP1110-Ab-2; GM-Tg-equg-IP1110-Ab-1/ GM-Tg-equg-IP1110-Ab-2
Products NameAnti-LRIT3 monoclonal antibody
Formatmab
Target NameLRIT3
Protein Sub-locationIntrocelluar Protein
Category of antibodyCytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-LRIT3 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1110-Ag-1Recombinant multi-species LRIT3/ CSNB1F/ FIGLER4 protein
    CytokineGM-Tg-g-IP1110-Ag-1leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 (LRIT3) protein


    Target information

    Target IDGM-IP1110
    Target NameLRIT3
    Gene ID345193,242235,502596,698360,610534,101083079,511618,100072841
    Gene Symbol and SynonymsCSNB1F,FIGLER4,Gm421,LRIT3,RGD1559637
    Uniprot AccessionQ3SXY7
    Uniprot Entry NameLRIT3_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryCytokine Target
    DiseaseN/A
    Gene EnsemblENSG00000183423
    Target ClassificationN/A

    The target: LRIT3, gene name: LRIT3, also named as CSNB1F, FIGLER4. This gene encodes a protein that has a fibronectin type III domain and a C-terminal transmembrane domain, as well as a leucine-rich repeat domain and immunoglobulin-like domain near the N-terminus. The encoded protein may regulate fibroblast growth factor receptors and affect the modification of these receptors, which are glycosylated differently in the Golgi and endoplasmic reticulum. Mutations in this gene are associated with congenital stationary night blindness, type 1F. [provided by RefSeq, May 2013].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.